1. Home
  2. GRI vs UCAR Comparison

GRI vs UCAR Comparison

Compare GRI & UCAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$2.18

Market Cap

3.3M

Sector

Health Care

ML Signal

HOLD

Logo U Power Limited

UCAR

U Power Limited

HOLD

Current Price

$1.31

Market Cap

2.8M

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRI
UCAR
Founded
2018
2013
Country
United States
China
Employees
N/A
80
Industry
Biotechnology: Pharmaceutical Preparations
Retail-Auto Dealers and Gas Stations
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
2.8M
IPO Year
2020
2022

Fundamental Metrics

Financial Performance
Metric
GRI
UCAR
Price
$2.18
$1.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$160.00
$50.00
AVG Volume (30 Days)
34.1K
3.0M
Earning Date
05-15-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.18
$0.04
52 Week High
$6.70
$4.98

Technical Indicators

Market Signals
Indicator
GRI
UCAR
Relative Strength Index (RSI) 44.50 45.98
Support Level $2.12 $1.14
Resistance Level $2.23 $1.71
Average True Range (ATR) 0.12 0.16
MACD -0.01 -0.06
Stochastic Oscillator 51.16 4.32

Price Performance

Historical Comparison
GRI
UCAR

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

About UCAR U Power Limited

U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.

Share on Social Networks: